Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis

Eric S. Surrey, Ahmed M. Soliman, Sanjay K. Agarwal, Michael C. Snabes, Michael Peter Diamond

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of elagolix, an oral GnRH antagonist, for the reduction of fatigue in women with moderate or severe endometriosis-associated pain. Design: Randomized, double-blind, multicenter, placebo-controlled phase III trial. Setting: Clinics. Patient(s): A total of 860 women treated with elagolix or placebo. Intervention(s): Women received either elagolix at 150 mg daily (QD) orally, elagolix at 200 mg twice daily (BID) orally, or placebo. Main Outcome Measure(s): Change from baseline to month 1, 3, and 6 visits, in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 6a questionnaire T-scores. Results(s): At baseline, 54%–74% of women with moderate to severe pain associated with endometriosis reported having fatigue-related issues “quite a bit” or “very much,” depending on the question asked. Fatigue extent was reduced to 29%–43% and 14%–29% for women treated with elagolix at 150 mg QD and 200 mg BID, respectively, at 6 months, compared with 35%–50% with placebo. The resultant decrease in fatigue T-scores was significant after elagolix treatment compared with placebo at 6 months, with changes of −2.21 and −5.90 with elagolix at 150 mg QD and 200 mg BID, respectively. Significant reduction in fatigue scores were observed among patients reporting clinically meaningful response “reduction” in dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia (−7.31, −6.62, and −4.31, respectively) compared with nonresponders. Conclusion(s): In women with moderate to severe endometriosis related pain, elagolix significantly reduces fatigue levels.

Original languageEnglish (US)
Pages (from-to)298-304.e3
JournalFertility and sterility
Volume112
Issue number2
DOIs
StatePublished - Aug 1 2019

Fingerprint

Endometriosis
Fatigue
Pain
Placebos
Therapeutics
Dyspareunia
Dysmenorrhea
Pelvic Pain
elagolix
Information Systems
Gonadotropin-Releasing Hormone
Outcome Assessment (Health Care)

Keywords

  • Endometriosis
  • elagolix
  • fatigue
  • gonadotropin-releasing hormone antagonist

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. / Surrey, Eric S.; Soliman, Ahmed M.; Agarwal, Sanjay K.; Snabes, Michael C.; Diamond, Michael Peter.

In: Fertility and sterility, Vol. 112, No. 2, 01.08.2019, p. 298-304.e3.

Research output: Contribution to journalArticle

Surrey, Eric S. ; Soliman, Ahmed M. ; Agarwal, Sanjay K. ; Snabes, Michael C. ; Diamond, Michael Peter. / Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. In: Fertility and sterility. 2019 ; Vol. 112, No. 2. pp. 298-304.e3.
@article{941f1c874fa3454cb099d871a9953870,
title = "Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis",
abstract = "Objective: To evaluate the efficacy of elagolix, an oral GnRH antagonist, for the reduction of fatigue in women with moderate or severe endometriosis-associated pain. Design: Randomized, double-blind, multicenter, placebo-controlled phase III trial. Setting: Clinics. Patient(s): A total of 860 women treated with elagolix or placebo. Intervention(s): Women received either elagolix at 150 mg daily (QD) orally, elagolix at 200 mg twice daily (BID) orally, or placebo. Main Outcome Measure(s): Change from baseline to month 1, 3, and 6 visits, in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 6a questionnaire T-scores. Results(s): At baseline, 54{\%}–74{\%} of women with moderate to severe pain associated with endometriosis reported having fatigue-related issues “quite a bit” or “very much,” depending on the question asked. Fatigue extent was reduced to 29{\%}–43{\%} and 14{\%}–29{\%} for women treated with elagolix at 150 mg QD and 200 mg BID, respectively, at 6 months, compared with 35{\%}–50{\%} with placebo. The resultant decrease in fatigue T-scores was significant after elagolix treatment compared with placebo at 6 months, with changes of −2.21 and −5.90 with elagolix at 150 mg QD and 200 mg BID, respectively. Significant reduction in fatigue scores were observed among patients reporting clinically meaningful response “reduction” in dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia (−7.31, −6.62, and −4.31, respectively) compared with nonresponders. Conclusion(s): In women with moderate to severe endometriosis related pain, elagolix significantly reduces fatigue levels.",
keywords = "Endometriosis, elagolix, fatigue, gonadotropin-releasing hormone antagonist",
author = "Surrey, {Eric S.} and Soliman, {Ahmed M.} and Agarwal, {Sanjay K.} and Snabes, {Michael C.} and Diamond, {Michael Peter}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.fertnstert.2019.02.031",
language = "English (US)",
volume = "112",
pages = "298--304.e3",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis

AU - Surrey, Eric S.

AU - Soliman, Ahmed M.

AU - Agarwal, Sanjay K.

AU - Snabes, Michael C.

AU - Diamond, Michael Peter

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Objective: To evaluate the efficacy of elagolix, an oral GnRH antagonist, for the reduction of fatigue in women with moderate or severe endometriosis-associated pain. Design: Randomized, double-blind, multicenter, placebo-controlled phase III trial. Setting: Clinics. Patient(s): A total of 860 women treated with elagolix or placebo. Intervention(s): Women received either elagolix at 150 mg daily (QD) orally, elagolix at 200 mg twice daily (BID) orally, or placebo. Main Outcome Measure(s): Change from baseline to month 1, 3, and 6 visits, in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 6a questionnaire T-scores. Results(s): At baseline, 54%–74% of women with moderate to severe pain associated with endometriosis reported having fatigue-related issues “quite a bit” or “very much,” depending on the question asked. Fatigue extent was reduced to 29%–43% and 14%–29% for women treated with elagolix at 150 mg QD and 200 mg BID, respectively, at 6 months, compared with 35%–50% with placebo. The resultant decrease in fatigue T-scores was significant after elagolix treatment compared with placebo at 6 months, with changes of −2.21 and −5.90 with elagolix at 150 mg QD and 200 mg BID, respectively. Significant reduction in fatigue scores were observed among patients reporting clinically meaningful response “reduction” in dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia (−7.31, −6.62, and −4.31, respectively) compared with nonresponders. Conclusion(s): In women with moderate to severe endometriosis related pain, elagolix significantly reduces fatigue levels.

AB - Objective: To evaluate the efficacy of elagolix, an oral GnRH antagonist, for the reduction of fatigue in women with moderate or severe endometriosis-associated pain. Design: Randomized, double-blind, multicenter, placebo-controlled phase III trial. Setting: Clinics. Patient(s): A total of 860 women treated with elagolix or placebo. Intervention(s): Women received either elagolix at 150 mg daily (QD) orally, elagolix at 200 mg twice daily (BID) orally, or placebo. Main Outcome Measure(s): Change from baseline to month 1, 3, and 6 visits, in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 6a questionnaire T-scores. Results(s): At baseline, 54%–74% of women with moderate to severe pain associated with endometriosis reported having fatigue-related issues “quite a bit” or “very much,” depending on the question asked. Fatigue extent was reduced to 29%–43% and 14%–29% for women treated with elagolix at 150 mg QD and 200 mg BID, respectively, at 6 months, compared with 35%–50% with placebo. The resultant decrease in fatigue T-scores was significant after elagolix treatment compared with placebo at 6 months, with changes of −2.21 and −5.90 with elagolix at 150 mg QD and 200 mg BID, respectively. Significant reduction in fatigue scores were observed among patients reporting clinically meaningful response “reduction” in dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia (−7.31, −6.62, and −4.31, respectively) compared with nonresponders. Conclusion(s): In women with moderate to severe endometriosis related pain, elagolix significantly reduces fatigue levels.

KW - Endometriosis

KW - elagolix

KW - fatigue

KW - gonadotropin-releasing hormone antagonist

UR - http://www.scopus.com/inward/record.url?scp=85064202180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064202180&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2019.02.031

DO - 10.1016/j.fertnstert.2019.02.031

M3 - Article

AN - SCOPUS:85064202180

VL - 112

SP - 298-304.e3

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 2

ER -